Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexapro

- PMLiVE

EMA recommends approval for alcohol dependency drug

Lundbeck’s Selincro to be used in conjunction with psychosocial support

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Teva plans revamp as 2013 revenues expected to fall short

Expects increased competition for biggest-selling drug Copaxone

- PMLiVE

Lundbeck revenues fall on Lexapro competition

Reinforces need for successful vortioxetine launch

Bristol-Myers Squibb (BMS) building

BMS cuts salesforce on revised Abilify deal

Nearly 500 jobs to go as US rights to schizophrenia blockbuster return to Otsuka

- PMLiVE

Abbott cuts 550 jobs as Q3 sales stay flat

Layoffs come as company prepares to spin off its pharma division as AbbVie

Lexapro generics hammer Forest Labs’ Q3 results

Sales down by nearly 40 per cent

- PMLiVE

GSK reverses closure of Irish manufacturing facility

But will initially cut staff numbers at Stiefel's Sligo plant by a third

- PMLiVE

Sanofi plans 900 job cuts in France in upheaval of research

Future of Toulouse site remains in balance

Lundbeck files novel antidepressant vortioxetine in EU

Could counter loss of patent for big-selling Lexapro/Cipralex

- PMLiVE

Targacept to cut more jobs after ADHD trial failure

TC-5619 disappoints in phase II trial after missing primary endpoint

- PMLiVE

Sanofi to announce up to 2,500 job cuts next week says paper

Le Figaro claims losses will mainly affect France

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links